Detailed Information
Cited 2 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.
- Authors
- Finn, RS[Finn, Richard S.]; Edeline, J[Edeline, Julien]; Bouattour, M[Bouattour, Mohamed]; Cheng, AL[Cheng, Ann-Lii]; Chan, SL[Chan, Stephen Lam]; Yau, T[Yau, Thomas]; Garrido, M[Garrido, Marcelo]; Knox, JJ[Knox, Jennifer J.]; Daniele, B[Daniele, Bruno]; Zhu, AX[Zhu, Andrew X.]; Breder, VV[Breder, Valeriy Vladimirovich]; Lim, HY[Lim, Ho Yeong]; Ogasawara, S[Ogasawara, Sadahisa]; Siegel, AB[Siegel, Abby B.]; Rahman, A[Rahman, Ahmadur]; Wei, ZW[Wei, Ziwen]; Merle, P[Merle, Philippe]
- Issue Date
- 20-May-2021
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.39, no.15
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 39
- Number
- 15
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.